Figure 5
From: Killing cancer cells by targeted drug-carrying phage nanomedicines
Toxicity analysis of targeted drug carrying phages by in vitro cell-killing assays. A) Hygromycin carrying phages on SKBR3 target cells SKBR3 cells were incubated with 5 × 1011 of hygromycin carrying fUSE5-ZZ-chFRP5 phages (a), hygromycin carrying fUSE5-ZZ-human IgG (b), hygromycin carrying fUSE5-ZZ-human IgG (c), 2 mg free hygromycin/well (d), 0.2 mg free hygromycin/well (e), 0.02 mg free hygromycin/well (f) 0.002 mg free hygromycin/well (g). B) Hygromycin carrying phages on HEK293 non-target cells HEK293 cells were incubated with 5 × 1011 of hygromycin carrying fUSE5-ZZ-human IgG phages (a), hygromycin carrying fUSE5-ZZ-trastuzumab phages (b), hygromycin carrying fUSE5-ZZ-cetuximab phages (c), 1 mg/ml free hygromycin (d), 0.1 mg/ml free hygromycin (e), 0.01 mg/ml free hygromycin (f). C) Trastuzumab-targeted, doxorubicin carrying phages on SKBR3 target cells SKBR cells were incubated with serial dilutions of doxorubicin carrying phages; Grey bars, doxorubicin carrying fUSE5-ZZ-trastuzumab, Black bars fUSE5-ZZ-(p8)DFK-human IgG, white bars, doxorubicin carrying fUSE5-ZZ-(p8)DFK-trastuzumab. D) Cetuximab-targeted, doxorubicin carrying phages on A431 target cells A431 cells were incubated with serial dilutions of doxorubicin carrying phages; Grey bars, doxorubicin carrying fUSE5-ZZ-cetuximab, Black bars fUSE5-ZZ-(p8)DFK-human IgG White bars, doxorubicin carrying fUSE5-ZZ-(p8)DFK-cetuximab. The relative number of viable cells was determined using an enzymatic MTT assay and is indicated as the absorption at 570 nm. The results are expressed as percentage of living cells respect to untreated controls. Data represent mean values ± SD of three independent experiments.